Axsome Therapeutics (AXSM) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $161.79, -0.27% vs the prior close of $162.22.
- Volume 802.60K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AXSM ends flat (-0.3%) to $161.79. Closed at $161.79, -0.27% vs the prior close of $162.22. Day range $160.27–$169.96, opened at $163.44.
AXSM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — AXSM ends flat (-0.3%) to $161.79
- Closed at $161.79, -0.27% vs the prior close of $162.22. Day range $160.27–$169.96, opened at $163.44.
- Volume was 802.60K shares, 1.1x its 50-day average of 737.32K.
- Price is -18.7% vs its 50-day average ($199.00) and -19.3% vs its 200-day average ($200.53).
- 52-week range $123.42–$260.19; today's close sits at 28% of that range, 37.8% below the 52-week high.
Oct 14, 2026 — AXSM jumps 3.8% to $162.22
- Closed at $162.22, +3.77% vs the prior close of $156.32. Day range $155.18–$164.00, opened at $156.44.
- Volume was 893.20K shares, 1.2x its 50-day average of 728.93K.
- Price is -18.9% vs its 50-day average ($200.02) and -19.1% vs its 200-day average ($200.48).
- 52-week range $120.12–$260.19; today's close sits at 30% of that range, 37.7% below the 52-week high.
Oct 13, 2026 — AXSM slides 5.8% to $156.32, a 6-month low on 1.8x normal volume
- Closed at $156.32, -5.83% vs the prior close of $166.00. Day range $155.68–$166.55, opened at $166.01.
- Volume was 1.33M shares, 1.8x its 50-day average of 721.61K — unusually heavy trading.
- Price is -22.2% vs its 50-day average ($201.02) and -22.0% vs its 200-day average ($200.43).
- 52-week range $119.20–$260.19; today's close sits at 26% of that range, 39.9% below the 52-week high.
- That makes 13 straight losses.
Oct 12, 2026 — AXSM dips 1.4% to $166.00, a 6-month low, 12 down days in a row
- Closed at $166.00, -1.40% vs the prior close of $168.35. Day range $165.02–$170.80, opened at $169.50.
- Volume was 663.00K shares, 0.9x its 50-day average of 723.99K.
- Price is -17.9% vs its 50-day average ($202.12) and -17.2% vs its 200-day average ($200.41).
- 52-week range $119.20–$260.19; today's close sits at 33% of that range, 36.2% below the 52-week high.
- That makes 12 straight losses.
Oct 9, 2026 — AXSM dips 1.0% to $168.35, a 6-month low, 11 down days in a row
- Closed at $168.35, -1.02% vs the prior close of $170.08. Day range $166.12–$170.64, opened at $170.18.
- Volume was 894.50K shares, 1.2x its 50-day average of 720.39K.
- Price is -17.1% vs its 50-day average ($203.16) and -16.0% vs its 200-day average ($200.36).
- 52-week range $118.71–$260.19; today's close sits at 35% of that range, 35.3% below the 52-week high.
- That makes 11 straight losses.
Oct 8, 2026 — AXSM dips 1.7% to $170.08, a 6-month low, 10 down days in a row
- Closed at $170.08, -1.67% vs the prior close of $172.97. Day range $166.21–$172.27, opened at $170.09.
- Volume was 1.07M shares, 1.5x its 50-day average of 709.38K.
- Price is -16.8% vs its 50-day average ($204.48) and -15.1% vs its 200-day average ($200.29).
- 52-week range $117.30–$260.19; today's close sits at 37% of that range, 34.6% below the 52-week high.
- That makes 10 straight losses.
Oct 7, 2026 — AXSM dips 0.8% to $172.97, a 6-month low, 9 down days in a row
- Closed at $172.97, -0.79% vs the prior close of $174.34. Day range $172.48–$177.91, opened at $174.00.
- Volume was 887.30K shares, 1.3x its 50-day average of 699.71K.
- Price is -15.9% vs its 50-day average ($205.63) and -13.6% vs its 200-day average ($200.20).
- 52-week range $117.30–$260.19; today's close sits at 39% of that range, 33.5% below the 52-week high.
- That makes 9 straight losses.
Oct 6, 2026 — AXSM dips 1.5% to $174.34, a 3-month low on 2.0x normal volume
- Closed at $174.34, -1.55% vs the prior close of $177.08. Day range $169.30–$176.52, opened at $176.52.
- Volume was 1.37M shares, 2.0x its 50-day average of 687.82K — unusually heavy trading.
- Price is -15.7% vs its 50-day average ($206.85) and -12.9% vs its 200-day average ($200.07).
- 52-week range $117.30–$260.19; today's close sits at 40% of that range, 33.0% below the 52-week high.
- That makes 8 straight losses.
Oct 5, 2026 — AXSM dips 1.2% to $177.08, a 3-month low, 7 down days in a row
- Closed at $177.08, -1.21% vs the prior close of $179.25. Day range $175.73–$179.70, opened at $179.25.
- Volume was 858.90K shares, 1.3x its 50-day average of 679.88K.
- Price is -14.9% vs its 50-day average ($208.14) and -11.4% vs its 200-day average ($199.94).
- 52-week range $117.30–$260.19; today's close sits at 42% of that range, 31.9% below the 52-week high.
- That makes 7 straight losses.
Oct 2, 2026 — AXSM dips 1.5% to $179.25, a 3-month low, 6 down days in a row
- Closed at $179.25, -1.55% vs the prior close of $182.07. Day range $175.46–$182.55, opened at $182.55.
- Volume was 981.40K shares, 1.5x its 50-day average of 670.26K.
- Price is -14.4% vs its 50-day average ($209.41) and -10.3% vs its 200-day average ($199.79).
- 52-week range $117.30–$260.19; today's close sits at 43% of that range, 31.1% below the 52-week high.
- That makes 6 straight losses.
AXSM latest news & SEC filings
Every SEC filing by or about AXSM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 3, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jacobson Mark L. sold 10,000 shares at $208.65 (≈$2.09M) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 10, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $218.38M (prior year $150.04M) (+45.5% vs Jun 30, 2025)
- Net income: -$51.31M (prior year -$47.97M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.99 (prior year -$0.97) (loss widened vs Jun 30, 2025)
Aug 10, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tabuteau Herriot sold 4,660 shares at $213.95 (≈$997.01K) on Aug 6, 2026
- Tabuteau Herriot sold 45,004 shares at $212.01 (≈$9.54M) on Aug 5, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 27, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 1, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tabuteau Herriot sold 49,666 shares at $240.25 (≈$11.93M) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade AXSM
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 4, 2026, Feb 23, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.89% (largest 5.8%).
- Liquidity: about 879.00K shares (≈$142.21M) trade per day on average.
- 52-week position: $161.79 vs a range of $123.42–$260.19 (28% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Mark L. Jacobson sold 10,000 shares on Sep 3, 2026.
- Latest filings: 10-Q Aug 10, 2026; 8-K Aug 10, 2026; 8-K Jul 15, 2026.
- Share count: 52.38M shares outstanding (Aug 3, 2026), +5.0% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AXSM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 163.44 | 169.96 | 160.27 | 161.79 | 802.60K |
| Oct 14, 2026 | 156.44 | 164.00 | 155.18 | 162.22 | 893.20K |
| Oct 13, 2026 | 166.01 | 166.55 | 155.68 | 156.32 | 1.33M |
| Oct 12, 2026 | 169.50 | 170.80 | 165.02 | 166.00 | 663.00K |
| Oct 9, 2026 | 170.18 | 170.64 | 166.12 | 168.35 | 894.50K |
| Oct 8, 2026 | 170.09 | 172.27 | 166.21 | 170.08 | 1.07M |
| Oct 7, 2026 | 174.00 | 177.91 | 172.48 | 172.97 | 887.30K |
| Oct 6, 2026 | 176.52 | 176.52 | 169.30 | 174.34 | 1.37M |
| Oct 5, 2026 | 179.25 | 179.70 | 175.73 | 177.08 | 858.90K |
| Oct 2, 2026 | 182.55 | 182.55 | 175.46 | 179.25 | 981.40K |
| Oct 1, 2026 | 184.39 | 185.67 | 181.75 | 182.07 | 660.20K |
| Sep 30, 2026 | 186.51 | 188.00 | 184.00 | 184.39 | 1.03M |
| Sep 29, 2026 | 191.41 | 194.25 | 182.10 | 186.14 | 1.58M |
| Sep 28, 2026 | 194.98 | 198.96 | 193.11 | 193.89 | 707.40K |
| Sep 25, 2026 | 197.68 | 201.42 | 194.35 | 195.09 | 838.20K |
| Sep 24, 2026 | 193.02 | 197.11 | 190.72 | 196.03 | 386.10K |
| Sep 23, 2026 | 204.01 | 204.70 | 189.05 | 193.45 | 913.00K |
| Sep 22, 2026 | 205.68 | 207.01 | 202.52 | 203.10 | 299.80K |
| Sep 21, 2026 | 208.17 | 210.85 | 203.38 | 205.49 | 543.50K |
| Sep 18, 2026 | 212.05 | 213.26 | 206.92 | 207.78 | 869.30K |
About Axsome Therapeutics
Axsome Therapeutics (AXSM) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1579428.
AXSM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mark Coleman | Director | Jun 10, 2026 |
| Roger Jeffs | Director | Jun 11, 2026 |
| Susan Mahony | Director | Jun 10, 2026 |
| Mark E Saad | Director | Jun 10, 2026 |
| Herriot Tabuteau | Chief Executive Officer | Aug 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mark L. Jacobson | Chief Operating Officer | Sep 3, 2026 |
| Ari Maizel | Chief Commercial Officer | Apr 23, 2026 |
| Hunter R. Murdock | General Counsel | Apr 23, 2026 |
| Nick Pizzie | Chief Financial Officer | Jun 9, 2026 |
| Herriot Tabuteau | Chief Executive Officer | Aug 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Mark L. Jacobson | Sale | 10,000 | $208.65 |
| Aug 6, 2026 | Herriot Tabuteau | Sale | 4,660 | $213.95 |
| Aug 5, 2026 | Herriot Tabuteau | Sale | 45,004 | $212.01 |
| Jul 1, 2026 | Herriot Tabuteau | Sale | 49,666 | $240.25 |
| Jun 11, 2026 | Roger Jeffs | Sale | 286 | $249.12 |
| Jun 10, 2026 | Roger Jeffs | Sale | 286 | $246.18 |
| Jun 10, 2026 | Susan Mahony | Sale | 300 | $246.18 |
| Jun 10, 2026 | Mark Coleman | Sale | 643 | $249.00 |
| Jun 9, 2026 | Susan Mahony | Sale | 300 | $237.21 |
| Jun 9, 2026 | Nick Pizzie | Sale | 33,000 | $240.09 |
| Jun 9, 2026 | Herriot Tabuteau | Sale | 49,670 | $241.01 |
| Jun 2, 2026 | Mark Coleman | Sale | 5,537 | $223.39 |
| Jun 1, 2026 | Mark Coleman | Sale | 6,000 | $230.30 |
| May 29, 2026 | Mark Coleman | Sale | 6,000 | $233.46 |
| May 5, 2026 | Mark L. Jacobson | Sale | 233 | $228.18 |
AXSM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $638.50M | $-183.17M | -3.68 | $-93.41M |
| Dec 31, 2024 | $385.69M | $-287.22M | -5.99 | $-128.41M |
| Dec 31, 2023 | $270.60M | $-239.24M | -5.27 | $-145.08M |
| Dec 31, 2022 | $50.04M | $-187.13M | -4.60 | $-116.51M |
| Dec 31, 2021 | — | $-130.40M | -3.47 | $-108.23M |
Latest balance sheet: total assets $761.45M, total liabilities $678.14M, cash $319.85M (as of Jun 30, 2026).
AXSM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $220.89 |
| May 4, 2026 | 8-K Item 2.02 (results) | $223.70 |
| Feb 23, 2026 | 8-K Item 2.02 (results) | $174.76 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $176.82 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $135.75 |
| Aug 4, 2025 | 8-K Item 2.02 (results) | $106.54 |
| May 5, 2025 | 8-K Item 2.02 (results) | $116.49 |
| Feb 18, 2025 | 8-K Item 2.02 (results) | $128.09 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $89.27 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $99.49 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on AXSM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.